Crossbow Therapeutics, Inc., is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company’s T-Bolt™ therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets. Crossbow’s efficient and selective approach is designed to target the entire universe of cancer proteins, dramatically expanding the potential of antibody therapy to address many types of cancer.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $80M
Founded date: 2021
Investors 2
| Date | Name | Website |
| 18.07.2023 | MPM Capita... | mpmcapital... |
| - | MPM BioImp... | mpmbioimpa... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 10.07.2023 | Series A | $80M | - |
Mentions in press and media 6
| Date | Title | Description |
| 22.03.2026 | Crossbow Therapeutics Fuels T-Cell Engager Pipeline with $77 Million Series B | Crossbow Therapeutics secured $77 million in Series B funding to propel its innovative TCR-mimetic antibody cancer therapies. This substantial capital injection will accelerate the development of critical T-cell engager programs. Funds will... |
| 19.03.2026 | Crossbow Therapeutics Raises $77M in Series B Funding | Crossbow Therapeutics, a Cambridge, MA-based biotechnology company developing antibody therapies to treat a broad range of cancers, raised $77M in Series B funding. The round was led by Taiho Ventures and Arkin Bio Capital, with participati... |
| 18.03.2026 | Crossbow hits $77M series B round to bankroll quiver of T-Bolts | Crossbow Therapeutics has successfully hit a $77 million series B round, which the biotech will use to fund a trial of its lead T-cell engager (TCE) and fill its quiver with more T-Bolts. The latest financing was co-led by Taiho Ventures an... |
| 11.07.2023 | Crossbow Therapeutics Raises $80M in Series A Financing | Crossbow Therapeutics, a Cambridge, MA-based biotechnology company developing a novel class of antibody therapies to treat a broad range of cancers, raised $80M in Series A funding. The round was led by MPM BioImpact and Pfizer Ventures, wi... |
| - | Crossbow Therapeutics | “Expanding the reach of antibody therapeutics. Determined to revolutionize the reach of cancer treatment by developing potent and precise therapies that can target the entire universe of cancer antigens.” |
| - | Crossbow Therapeutics | “Expanding the reach of antibody therapeutics. Crossbow Therapeutics is determined to revolutionize the reach of cancer treatment by developing potent and precise therapies that can target the entire universe of cancer antigens.” |